Loading
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors | New England Journal of Medicine | 2017 |
| FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 | European Journal of Nuclear Medicine and Molecular Imaging | 2010 |
| German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients | Journal of Nuclear Medicine | 2017 |
These papers come from a Europe PMC search on the author's name and institution, taking the most cited articles.
Shares PSMA PET, Radioligand therapy (beta emitters) and the tag leadership.
Shares Prostate cancer and the tag leadership.
Shares Neuroendocrine tumours, Prostate cancer and the tag leadership.
Shares Neuroendocrine tumours and the tag leadership.
Shares Prostate cancer and the tag leadership.
Shares Prostate cancer and the tag leadership.
Shares Prostate cancer and the tag leadership.